Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical impr...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Arthritis Rheumatol
Главные авторы: Deakin, Claire T., Campanilho‐Marques, Raquel, Simou, Stefania, Moraitis, Elena, Wedderburn, Lucy R., Pullenayegum, Eleanor, Pilkington, Clarissa A.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2018
Предметы:
Pediatric Rheumatology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947636/
https://ncbi.nlm.nih.gov/pubmed/29342499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40418
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы